MX2019009063A - Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. - Google Patents

Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.

Info

Publication number
MX2019009063A
MX2019009063A MX2019009063A MX2019009063A MX2019009063A MX 2019009063 A MX2019009063 A MX 2019009063A MX 2019009063 A MX2019009063 A MX 2019009063A MX 2019009063 A MX2019009063 A MX 2019009063A MX 2019009063 A MX2019009063 A MX 2019009063A
Authority
MX
Mexico
Prior art keywords
fusion proteins
making
factor
methods
same
Prior art date
Application number
MX2019009063A
Other languages
English (en)
Inventor
Seth Chhabra Ekta
Kulman John
Liu Tongyao
t peters Robert
Liu Zhiqian
Van Der Flier Arjan
R Light David
ISMAIL Ayman
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of MX2019009063A publication Critical patent/MX2019009063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

La presente descripción proporciona proteínas de fusión del factor IX (FIX) que comprenden al menos un resto heterólogo, tal como un XTEN. La presente descripción describe además métodos para preparar y utilizar las proteínas de fusión del FIX.
MX2019009063A 2017-01-31 2018-01-31 Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. MX2019009063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762452826P 2017-01-31 2017-01-31
PCT/US2018/016277 WO2018144623A1 (en) 2017-01-31 2018-01-31 Factor ix fusion proteins and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2019009063A true MX2019009063A (es) 2019-10-21

Family

ID=61193175

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009063A MX2019009063A (es) 2017-01-31 2018-01-31 Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.

Country Status (19)

Country Link
US (1) US20210238259A1 (es)
EP (1) EP3576762A1 (es)
JP (1) JP2020505424A (es)
KR (1) KR20190112763A (es)
CN (1) CN110831613A (es)
AR (1) AR110871A1 (es)
AU (1) AU2018215092A1 (es)
BR (1) BR112019015569A2 (es)
CA (1) CA3051862A1 (es)
CL (1) CL2019002155A1 (es)
CR (1) CR20190389A (es)
EA (1) EA201991768A1 (es)
IL (1) IL268234A (es)
MA (1) MA47416A (es)
MX (1) MX2019009063A (es)
PH (1) PH12019501765A1 (es)
SG (1) SG11201906788XA (es)
TW (1) TW201831521A (es)
WO (1) WO2018144623A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
CN113817759B (zh) * 2020-07-10 2023-06-02 南京吉迈生物技术有限公司 修饰的因子ix、组合物、方法及其在基因治疗中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP2584443B2 (ja) 1985-04-22 1997-02-26 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 活性化▲ｉ▼▲ｘ▼因子の高収率産生
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
ATE148171T1 (de) 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
SG47099A1 (en) 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE236987T1 (de) 1992-11-13 2003-04-15 Idec Pharma Corp Konsensus-kozak-sequenzen zur säugetier- exprimierung
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
PT981637E (pt) 1997-03-14 2005-09-30 Biogen Idec Inc Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSED PROTEINS
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
BR0212035A (pt) 2001-09-04 2004-08-03 Merck Patent Gmbh Fator ix modificado
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
MX2007005466A (es) 2004-11-12 2007-10-19 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
WO2007021494A2 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
EP2084274A2 (en) 2006-06-19 2009-08-05 Nautilus Technology LLC Modified coagulation factor ix polypeptides and use thereof for treatment
JP2010503396A (ja) 2006-09-14 2010-02-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
PT2173890E (pt) 2007-06-21 2011-05-06 Tech Universit T M Nchen Prote?nas biologicamente activas com estabilidade in vivo e/ou in vitro aumentada
US20110154516A1 (en) 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
KR20110005862A (ko) 2008-04-16 2011-01-19 바이엘 헬스케어 엘엘씨 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
EP2282767A4 (en) 2008-04-16 2012-07-11 Bayer Healthcare Llc MODIFICATION OF FACTOR IX ORIENTED SITE
TWI573806B (zh) 2008-04-17 2017-03-11 巴克斯歐塔公司 生物活性胜肽
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
NZ596787A (en) 2009-06-08 2014-03-28 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
PT2506868T (pt) 2009-12-06 2018-02-23 Bioverativ Therapeutics Inc Polipéptidos quiméricos e hibridos de factor viii-fc, e métodos de utilização dos mesmos
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
TW201217526A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Chimeric clotting factors
MY192639A (en) 2010-07-09 2022-08-29 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
DK2882450T3 (da) 2012-07-11 2020-02-24 Bioverativ Therapeutics Inc Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
EA201890423A1 (ru) * 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения

Also Published As

Publication number Publication date
CA3051862A1 (en) 2018-08-09
US20210238259A1 (en) 2021-08-05
CR20190389A (es) 2019-11-26
BR112019015569A2 (pt) 2020-03-17
MA47416A (fr) 2019-12-11
TW201831521A (zh) 2018-09-01
EP3576762A1 (en) 2019-12-11
EA201991768A1 (ru) 2020-01-22
PH12019501765A1 (en) 2020-03-16
WO2018144623A1 (en) 2018-08-09
KR20190112763A (ko) 2019-10-07
IL268234A (en) 2019-09-26
CN110831613A (zh) 2020-02-21
CL2019002155A1 (es) 2020-02-21
AR110871A1 (es) 2019-05-08
JP2020505424A (ja) 2020-02-20
AU2018215092A1 (en) 2019-08-29
SG11201906788XA (en) 2019-08-27

Similar Documents

Publication Publication Date Title
PH12018500252A1 (en) Factor ix fusion protiens and methods of making and using same
AU2018351050A8 (en) Compositions and methods for selective protein degradation
WO2018109170A3 (en) Il-11ra antibodies
WO2018109174A3 (en) Il-11 antibodies
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
MY198059A (en) Anti-ox40 antibodies and their uses
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
SG10201803042PA (en) Anti-tim-3 antibodies
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MY191581A (en) Anti-pd-1 antibodies
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2022012042A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
PH12019501765A1 (en) Factor ix fusion proteins and methods of making and using same
EP3925979A3 (en) Fgfr-tacc fusion proteins and methods thereof
EP3503911A4 (en) COMPOSITIONS CONTAINING HYBRID ALBUMIN PROTEIN AND ANALOGUES THEREOF, PROCESSES FOR THE PRODUCTION AND USE OF THE SAME